Delayed inhaled carbon monoxide mediates the regression of established neointimal lesions

Michael Madigan1, Fateh Entabi1, Brian Zuckerbraun2

  • 1Department of Veterans Affairs Medical Center, University of Pittsburgh, Pittsburgh, Pa; Division of Vascular Surgery, University of Pittsburgh, Pittsburgh, Pa.

Abstract

Insights

Inhaled carbon monoxide (CO) effectively reduces established intimal hyperplasia lesions by inhibiting smooth muscle cell proliferation. This study demonstrates CO

Area of Science:

  • Vascular biology and regenerative medicine
  • Cardiovascular research
  • Pharmacology of inhaled gases

Background:

  • Intimal hyperplasia (IH) is a major cause of vascular intervention failure.
  • Few therapies can reverse established IH lesions.
  • Inhaled carbon monoxide (CO) shows promise in preventing and potentially reversing vascular changes.

Purpose of the Study:

  • To investigate the efficacy of inhaled CO in regressing established neointimal lesions.
  • To determine the cellular mechanisms underlying CO's effect on IH.

Main Methods:

  • Rats underwent carotid artery balloon angioplasty.
  • Inhaled CO treatment was administered from week 2 to week 4 post-injury.
  • Neointima size, apoptosis, proliferation, and autophagy were analyzed.

Main Results:

  • Delayed CO treatment significantly reduced established neointimal lesion size.
  • CO treatment markedly decreased smooth muscle cell proliferation.
  • Apoptosis and autophagy levels were not significantly increased by CO treatment.

Conclusions:

  • Inhaled CO can mediate the regression of established neointimal lesions.
  • The antiproliferative effect on smooth muscle cells is the primary mechanism.
  • CO offers a potential therapeutic strategy for vascular proliferative diseases.

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
613
Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
5.0K
COPD: Pathogenesis and Clinical Features01:20

COPD: Pathogenesis and Clinical Features

Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
2.1K